Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Authors:
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 272, 72-82
Abstract
No abstract availableKeywords
Funding Information
- NCI (R01CA101795)
- NIDA (R01DA030338)
- NIH (U54CA210181)
- Cancer Prevention and Research Institute of Texas (DP150099, RP150611, RP170537)
- Department of Defense (DoD) (BC151081)
- Golfer Against Cancer Foundation
This publication has 46 references indexed in Scilit:
- Multifaceted Immunomodulatory Nanoliposomes: Reshaping Tumors into Vaccines for Enhanced Cancer ImmunotherapyAdvanced Functional Materials, 2017
- Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host MortalityImmunity, 2016
- Immune Complexes Mimicking Synthetic Vaccine Nanoparticles for Enhanced Migration and Cross‐Presentation of Dendritic CellsAdvanced Functional Materials, 2016
- Analysis of drug combinations: current methodological landscapePharmacology Research & Perspectives, 2015
- Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon ResponseCell Reports, 2015
- Immune system targeting by biodegradable nanoparticles for cancer vaccinesJournal of Controlled Release, 2013
- Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug DeliveryAdvanced Materials, 2012
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- TLR signalling regulated antigen presentation in dendritic cellsCurrent Opinion in Immunology, 2010
- The DNA Sugar Backbone 2′ Deoxyribose Determines Toll-like Receptor 9 ActivationImmunity, 2008